CTRI/2022/07/043655尚未招募3 期
A Prospective, Open Label, Randomized, Controlled, Clinical Study To Evaluate The Safety And Efficacy Of Cardamom Extract (500mg tablet) In patients who have recovered from SARS -COV 2 infection
Zum Heilen Diagnostic and Therapeutics Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects aged 18-65 years of age and of either sex
- •2.Subjects who are willing to give consent to the study
- •3.Previously positive COVID cases along with comorbidity conditions
- •4.Can take oral medicines
- •5.Subject willing to abide by and comply with the study protocol
排除标准
- •1.Patients who are tested to be COVID-19 positive, at the time of enrollment in the study.
- •2.Patient with previous history of serious COPD, Asthma, Bronchiectesis and Chronic Cardiac ailments
- •3.Pregnant and lactating women
- •4.Patients who are not willing to volunteer for the study.
- •5.Patients developing serious complications, Immuno-compromisedpatients
- •6.Idiosyncratic reactions, severe medicinal aggravation and requiring ventilator support or emergency surgical intervention.
- •7.Age less than 18 years and more than 65 years
- •8.Any uncontrolled systemic disease, infection
- •9.Those with serious Cardiovascular, Cerebrovascular, Respiratory, Liver or Renal disease or any other disorder.
- •10.Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol
研究者
相似试验
招募中
3 期
Cardamom Extract Clinical trial on Covid patientsCTRI/2021/01/030601Zum Heilen Diagnostic Therapeutics ZH DT
招募中
4 期
Effect of high protein supplement on muscle strength, muscle mass andphysical function in elderly population.CTRI/2024/03/064441Hindustan Unilever Limited
招募中
3 期
Clinical trial on Covid 19 patientsCTRI/2021/04/033188Zum Heilen Diagnostic and Therapeutics Pvt Ltd120
已完成
3 期
A study of hormones in infertile women undergoing IVFCTRI/2019/10/021801Sanzyme P Ltd156
招募中
3 期
A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)gastroenteropancreatic neuroendocrine tumors10014713NL-OMON56413ITM Solucin GmbH20